Navigation Links
Moody's Raises Rating for Gerresheimer
Date:3/17/2008

DUSSELDORF, Germany, March 17 /PRNewswire-FirstCall/ -- The rating agency Moody's has raised the rating for the Gerresheimer Group from Ba3 to Ba2 with "Outlook stable".

As a result, the Group's financial standing in the market and its refinancing possibilities are substantially enhanced. Moody's justifies this step by reference to the considerably strengthened business profile as a result of successful acquisitions and in view of the Group's increased profitability and cash flow strength. In the detailed justification, Moody's emphasises the company's leading market position and its stable customer relationships in the pharmaceutical and cosmetics industries.

"We are very pleased about the better rating by Moody's. It confirms our successful business development and solid financial structure. On this basis we will again grow profitably in 2008," says Dr. Axel Herberg, CEO of Gerresheimer AG.

About Gerresheimer

Gerresheimer employs more than 10,800 people in 41 locations in Europe, America and Asia. In the financial year 2007, worldwide sales totalled EUR957.7m. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterized by high technical and regulatory barriers.

Contact Press

Burkhard Lingenberg

Director Corporate PR & Marketing

Telephone: +49-211-6181-250

Telefax: +49-211-6181-241

e-mail: b.lingenberg@gerresheimer.com e-mail

Contact Investor Relations

Anke Linnartz

Director Corporate Investor Relations

Telephone: +49-211-6181-314

Telefax: +49-211-6181-121

e-mail: a.
'/>"/>

SOURCE Gerresheimer AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. Enobia Pharma Raises $40.1 Million Series B Financing
3. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
4. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
5. VisEn Medical Raises $7 Million in Series B Financing
6. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
9. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
10. Anesiva Raises $45 Million in Common Stock Offering
11. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... hypothermic storage and cryopreservation freeze media ... tissues  ("BioLife" or the "Company"), today announced that it will ... 2015 (the "Annual Meeting"). Because the expected date ...
(Date:12/24/2014)... Earlier this year in a June 24 international conference ... Cell Technology Center, LLC ( ASCTC ) focused attention on ... tissue stem cells. His title “Asymmetric Self-Renewal by Distributed ... embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 According to Ross ... Island Affiliate of ITRA Global, the national office market continues ... recovery. This is evidenced by the third quarter’s surprising ... market. Low energy costs have held inflation down and ...
(Date:12/24/2014)... The report expects global cell isolation and expansion market to ... analyzed data about the vital drivers, restraints, trends, opportunities, strategies ... @ http://bit.ly/1yUxy0T , According to the report, the ... an impressive CAGR during near future. It expects this growth ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... 10:00 CET, AMSTERDAM, February 20 Amsterdam Molecular,Therapeutics (Euronext: AMT), ... full year 2007 results., Highlights - ... Cash & cash equivalents of EUR 51.3 million at June 30, ... AMT 011 - Positive results of Phase I/II in LPL ...
... new technologies launched onboard a U.S. Naval Academy satellite ... space. One technology is a sensor that can check ... "film" that can control heat. , These technologies were ... Md.; NASAs Ames Research Center, Moffett Field, Calif.; and ...
... a collaboration between researchers at the National Institute of ... of Kentucky potentially offers a low-cost way to mass ... sheets for a wide range of applications including flexible ... for field diagnostics. , In a paper posted this ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Reports Full Year Results 2007 2Amsterdam Molecular Therapeutics Reports Full Year Results 2007 3Amsterdam Molecular Therapeutics Reports Full Year Results 2007 4Amsterdam Molecular Therapeutics Reports Full Year Results 2007 5Amsterdam Molecular Therapeutics Reports Full Year Results 2007 6Amsterdam Molecular Therapeutics Reports Full Year Results 2007 7NASA MidSTAR-1 successful technologies may be revolutionary 2NASA MidSTAR-1 successful technologies may be revolutionary 3NASA MidSTAR-1 successful technologies may be revolutionary 4Directed self-ordering of organic molecules for electronic devices 2
(Date:1/22/2015)... Wis. , Jan. 15, 2015  BellBrook Labs, ... drug discovery, announced the launch of a TR-FRET ... the company,s Transcreener UDP Assay, a high throughput ... The new assay will allow for sensitive detection ...
(Date:1/22/2015)... 22, 2015 , Europe,s ... The European Patent Office to present a video retrospective of ... to be featured: Christofer Toumazou and Sophie Wilson ... and winners of the Award   Starting on 22 ...
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... Apollo Robbins for the 2015 International CES debut of ... Robbins will be at the NXT-ID booth January 6th ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... peculiarities with the DNA of just about every other plant ... as transposons, or "jumping genes," which have the ability to ... cell. An astounding 50% of human DNA ... former transposons that were active thousands to millions of years ...
... (Sept. 6, 2011) The American Physiological ... and the ENaC/Degenerin Family of Ion Channels, being held ... Grove, Calif. This scientific conference explores the connection ... growing global health concern. The five-day program ...
... surgeons are working together to improve the treatment of ... bone plates in the skull to fuse too soon. ... remove portions of the fused skull bones, and in ... -- requiring additional surgeries. Researchers in the Atlanta-based ...
Cached Biology News:A 'jumping gene's' preferred targets may influence genome evolution 2A 'jumping gene's' preferred targets may influence genome evolution 3Highlights of upcoming conference on aldosterone & the ENaC/Degenerin family of ion channels 2Developing technologies to improve the treatment of craniosynostosis in children 2Developing technologies to improve the treatment of craniosynostosis in children 3Developing technologies to improve the treatment of craniosynostosis in children 4
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
Request Info...
Biology Products: